Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL study

• During the first RSV season after the universal implementation of nirsevimab in Galicia (Spain), a large proportion of hospitalized infants had high-risk conditions, yet disease severity markers (oxygen need, ICU admission, NIVM) were comparable between breakthrough and non-breakthrough cases. • No signal of waning protection over time was observed among breakthrough cases, reinforcing the potential value of early, season-wide immunization.

Authors

Institutions

Publication Details

Journal
European Journal of Pediatrics
Published
2025-05-02
DOI
https://doi.org/10.1007/s00431-025-06151-3
Citations
4
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
5.42

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL study

Antonio Salas, Narmeen Mallah, Rolf Kramer, Ángela Manzanares et al.
4 citations
European Journal of Pediatrics
Respiratory viral infections research
5.42
article

Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE-GAL study

Antonio Salas, Narmeen Mallah, Rolf Kramer, Ángela Manzanares, Victoria Nartallo‐Penas, Marta Piñeiro-Sotelo, Carmen Durán‐Parrondo, Jacobo Pardo‐Seco, Juan‐Manuel González‐Pérez, Federico Martinón‐Torres, Ana Dacosta-Urbieta, Olaia Pérez‐Martínez, María‐Teresa Otero‐Barrós, Irene Rivero‐Calle, Susana Mirás‐Carballal, Leticia Platero-Alonso, Rosa‐María Alvárez‐Gil, Olga‐María Ces‐Ozores, Nuria Súarez‐Gaiche, Jing Jin, Carmen Rodríguez‐Tenreiro, María-Isolina Santiago-Pérez
article en
4 citations

Abstract

• During the first RSV season after the universal implementation of nirsevimab in Galicia (Spain), a large proportion of hospitalized infants had high-risk conditions, yet disease severity markers (oxygen need, ICU admission, NIVM) were comparable between breakthrough and non-breakthrough cases. • No signal of waning protection over time was observed among breakthrough cases, reinforcing the potential value of early, season-wide immunization.

European Journal of PediatricsVol. 184(5)
Universidade de Santiago de Compostela (ES), Xunta de Galicia (ES), Instituto de Salud Carlos III (ES), Sanofi (France) (FR), Complejo Hospitalario Universitario de Santiago (ES), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES), Instituto de Investigación Sanitaria de Santiago (ES), Servicio Gallego de Salud (ES)
AstraZeneca, Sanofi, Ministerio de Ciencia e Innovación, Xunta de Galicia, Universidade de Santiago de Compostela, European Regional Development Fund, Servicio Gallego de Salud
Good health and well-being
Openalex Percentile: Top 4%
Respiratory viral infections research
5.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.